0.76
VolitionRX Ltd (VNRX) 最新ニュース
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock By Investing.com - Investing.com India
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock - Investing.com
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure - MarketScreener
VolitionRx (NYSE:VNRX) Rating Increased to Strong-Buy at Jones Trading - Defense World
VolitionRX (VNRX) Coverage Initiated with a 'Buy' Rating by Jones Trading | VNRX Stock News - GuruFocus
JonesTrading Initiates Coverage on VolitionRx Limited With Buy Rating, $3 Price Target - marketscreener.com
Jones Trading initiates VolitionRX with Buy, sets $3 target By Investing.com - Investing.com India
VolitionRx (VNRX) Receives Buy Rating with Promising Price Targe - GuruFocus
VolitionRx initiated with a Buy at JonesResearch - TipRanks
VolitionRx (VNRX) Receives Buy Rating with Promising Price Target | VNRX Stock News - GuruFocus
Director Makes Bold Move with Major VolitionRX Stock Purchase - TipRanks
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Yahoo Finance
VolitionRx director Guy Innes buys $10,772 in common stock By Investing.com - Investing.com South Africa
VolitionRx director Guy Innes buys $10,772 in common stock - Investing.com
VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance
VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks
VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia
VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada
VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance
VolitionRx Reports Strong Q1 2025 Performance - TipRanks
VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria
Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com
Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
VolitionRX: Q1 Earnings Snapshot - CT Insider
VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat
Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks
Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus
VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance
VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com
VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - Yahoo Finance
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
VolitionRx enters new sales agreement, terminates old one - Investing.com Australia
VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa
大文字化:
|
ボリューム (24 時間):